{"name":"Aurobindo Pharma Ltd","slug":"aurobindo-pharma-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-06-30","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV-1-infection)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-23","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV, HIV Infections)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-01-01","label":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Phase 3 readout (Type 2 Diabetes)","drug":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","drugSlug":"dapagliflozin-metformin-hydrochloride","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-02-28","label":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE Phase 3 readout (Diabetes Mellitus, Type 2)","drug":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","drugSlug":"dapagliflozin-metformin-hydrochloride","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-08-01","label":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE Phase 3 readout (HIV-1-Infection)","drug":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","drugSlug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","genericName":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","slug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","indication":"Other","status":"marketed"},{"name":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","genericName":"DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE","slug":"dapagliflozin-metformin-hydrochloride","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Amphotericin B Liposome","genericName":"Amphotericin B Liposome","slug":"amphotericin-b-liposome","indication":"Infectious Disease","status":"marketed"}]}],"pipeline":[{"name":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","genericName":"DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE","slug":"dolutegravir-emtricitabine-and-tenofovir-alafenamide","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Amphotericin B Liposome","genericName":"Amphotericin B Liposome","slug":"amphotericin-b-liposome","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE","genericName":"DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE","slug":"dapagliflozin-metformin-hydrochloride","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-08","type":"regulatory","source":"Medical Dialogues","summary":"Aurobindo Pharma Secures USFDA Nod for Dapagliflozin-Metformin XR, Gains 180-Day Exclusivity - Medical Dialogues","headline":"Aurobindo Pharma Secures USFDA Nod for Dapagliflozin-Metformin XR, Gains 180-Day Exclusivity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPQktnWlBXWU9UZUJHYVN2WFhrbVRUa3FWQmo0QWoyNl9WNjVYb01rbEZhUmhlaENPRlJKZkNyMlZFVkZkR0s3WU9aUG5tb19LcVhpWXYzWmg2MGlXd0NsdmI0UnBFUE9ZNnRVUGFCSnRuQkc2c0hKNXBHb0ZncENndUF4VlRVM0JqRkpjZmc0M3Q1NDF4OTRobmxEWWRodWNLbWxFeTRNTkdFSG5BS25TTXlkdzFNVl8tMU1GMTRNQ0ZyRE5I?oc=5","date":"2026-04-08","type":"deal","source":"scanx.trade","summary":"Aurobindo Pharma Announces ₹800 Crore Share Buyback at ₹1,475 Per Share - scanx.trade","headline":"Aurobindo Pharma Announces ₹800 Crore Share Buyback at ₹1,475 Per Share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPM2FoYm1YTFc2eHZGWXRjRk5rMTN3VGhHRU14WGNVaGhXQTc0N1N1b1pUQXdjaC01d29SRlZyS2g5QV9ucWZQRkhjaU5NbmpaUmxla2RFYUtrNUFyWENOckY3Uy1FWlhpS1hEQWh2aVByeURURUJ5dmFoN3lQdEtKMVVLT0ZDX3RVU0V0UzdUQUdSUWtydm5lWmtHVlduWmR4Z091ZkpkRE9mVmJsODdZ?oc=5","date":"2026-04-08","type":"deal","source":"Markets Mojo","summary":"Aurobindo Pharma Ltd. is Rated Buy by MarketsMOJO - Markets Mojo","headline":"Aurobindo Pharma Ltd. is Rated Buy by MarketsMOJO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQOWdpZ0s2OGk1d0xZaFhCMGQ2NFRmTTdTTFoyclRnQXF0b2kzVk5GM1dmeUUzWFNRZFdBQUZRVG9GWEk4TFZxNHFrNHF4NG9JLXAxZV9Pc1A4RV8yR2VOLVhBdlVNeV91eGE3Q05nVmFmVjRNQWJ4WTJ3YjB5aDUtcEtSSmdSSktYQ1M1TkVvZlFBZzloeDFPWXB1bzBKbXV5anZwbTg1OGluWjlEMUY2dVhBN0hLR2JFNlBydXpTc0plUUVuZ2RWVWFLTQ?oc=5","date":"2026-04-07","type":"patent","source":"AD HOC NEWS","summary":"Aurobindo Pharma Ltd stock: Biosimilar win sparks fresh investor interest - AD HOC NEWS","headline":"Aurobindo Pharma Ltd stock: Biosimilar win sparks fresh investor interest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNVlhVdkFQdGRVSEhaYTNLblpMOUh4OThRUVFFTGdGMUJJN0N1X3I0RXNQMVZZMHRDX1NUVlNxS3VEazNUQjU0MENXbjFzbzFhbjVxaGZ5X0E3aEo1VHdnNlFhVjQtbjkyUmIwSEpsOE0xVUNCODJXd21TMkxEc2VpLXlPbzJTVjFQbkFMb3I2TEdVZGdtM0VQZkFtNm1CZTVMaTI1RtIBqgFBVV95cUxOYks3NjhWdzhPWXVyWlBrYkNWdWZHczFSR2dnUUMxMlRGTXR2NUpDMXdXdWZyVGUycU5ncDlwMjh1cDAwVHl6aWxRSG1NMlh6eXhhVm1HaXhTVGVkX2trWnhydDM5YTFadjJGR3l0N2h5TUwzQmJoRU5nZXM1QlhvWU9vS0ZGX2ZqSElLODJGV21oNFBhb2stZlVBM3hxcG84cTltdmJrMkxQZw?oc=5","date":"2026-04-07","type":"regulatory","source":"Devdiscourse","summary":"Aurobindo Pharma Gains USFDA Nod for Diabetes Drug - Devdiscourse","headline":"Aurobindo Pharma Gains USFDA Nod for Diabetes Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPeVZiQ3VMYnVzaDFJTmRQYkJVV2hpampod0lrb1g4RmdreUszQlNvZHV5bnNjeGZSVnJXYzZ2SU5BNTJSS1VHZ3Jhc19kek9vTG9sbVFpRjJvbHN1cHAtQ0t2cXlESVlZRm1ta1FpSEJFRXhrZVhnYzM5OGVqRFM2VTYwUHNrY3hxMUFxMHRKaHdYSFRYTTVQSDhxeVZOcUNwTHBPVHV6RU5na2xJeURMNGtEYWVYQlZQeF9OT2Y5WG50V3JJYlE?oc=5","date":"2026-04-06","type":"patent","source":"TipRanks","summary":"Aurobindo Pharma Transfers Domestic Branded Generics Business to Subsidiary - TipRanks","headline":"Aurobindo Pharma Transfers Domestic Branded Generics Business to Subsidiary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNNjRzUkNuLUZHSUNnQTVidXRJQk5OaFdUV2UybXplenk0c2pKZkpwRjd3Z3dUUHYyWGx1NnFzckprdElZekpVUmhPcHRLS0p6SDRkNzRiMWdma1pYb3VlZF81cFdJdks0MkhXMkNSd2JKY09Nc1IzM1hDcEo4T2I1b2xBYmV2bF93aTBjTm9vZUdoRWs0cDFzY2tHZ3lwOFZNZnVDckRR?oc=5","date":"2026-04-06","type":"deal","source":"marketscreener.com","summary":"Aurobindo Pharma Limited authorizes a Buyback Plan. - marketscreener.com","headline":"Aurobindo Pharma Limited authorizes a Buyback Plan.","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"earnings","source":"NDTV Profit","summary":"Aurobindo Pharma To Buy Back Shares Worth Rs 800 Crore — Check Record Date - NDTV Profit","headline":"Aurobindo Pharma To Buy Back Shares Worth Rs 800 Crore — Check Record Date","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE84Q2FmRWoyWW1kRFZUNUY5YjRvM3haY1RDVXVkR3F3TVJWTHR3OWRhMlRiVGZzaVdsWkZiMWdhX2xhSEhyY2VSb0VjWUJoM1JGazEtUjhhWEpOY1k1MUtUZDByWmRmZDBIdG1Tb0x3eXVIY0doSE9aclZB?oc=5","date":"2026-04-06","type":"pipeline","source":"Claim Depot","summary":"Aurobindo Irbesartan $2M Drug Contamination Settlement - Claim Depot","headline":"Aurobindo Irbesartan $2M Drug Contamination Settlement","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"deal","source":"Mint","summary":"Aurobindo Pharma declares buyback of shares at ₹1475. Size, record date, other details - Mint","headline":"Aurobindo Pharma declares buyback of shares at ₹1475. Size, record date, other details","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"regulatory","source":"CNBC TV18","summary":"Aurobindo Pharma approves ₹800 crore share buyback; Check premium, record date and more - CNBC TV18","headline":"Aurobindo Pharma approves ₹800 crore share buyback; Check premium, record date and more - CNBC TV18","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPQm5PYzM4UlUzeHlhU3MyRm5tRmM5UDhqUGZ2c1AzUzVoc202NkI0eXdsTG1Ybm05WVlHc2RjYkstRGFUV01BY0pkR3VVQXUwYzRLaXBZcXY5bGQtbG0wZnlfc2pzRmNXZDNmMW9lcXBRNkxZMjBjOGpvY2hRUWtUVGVtVUVNSG9YVDlNYUwxX1ZzYzJoRWh3U2t1anc2WDZWRXRUcHViZ3AzallwbUV3SV9CRGMxbkVycHN4UXYzOF9rY3FXVy1FTFQ0Yw?oc=5","date":"2026-01-05","type":"deal","source":"BDA Partners","summary":"BDA advises Khandelwal Labs on sale of non-oncology branded generics business to Aurobindo - BDA Partners","headline":"BDA advises Khandelwal Labs on sale of non-oncology branded generics business to Aurobindo","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}